原发性肝癌的治疗策略及药物研发进展
Treatment Strategy and Drug Development Progress of Primary Liver Cancer

随着医学研究的不断深入，原发性肝癌的治疗策略及药物研发取得了显著进展。本综述论文针对原发性肝癌，尤其是肝细胞癌(HCC)的疾病机制、流行病学、治疗方法和药物研发等方面的最新研究成果进行梳理。在疾病机制与生物标志物领域，研究聚焦于IVIM-DWI参数与VEGF和MMPs表达的相关性，及INK4位点反义非编码RNA的功能，为发现新的治疗靶点提供依据。流行病学与临床特征研究揭示了HCC在不同人群和年龄段的发病率变化，为疾病预防和早期干预提供数据支持。在治疗方面，包括传统的肝动脉化疗栓塞术及其与其他治疗方式的联合应用效果评估，以及针对性自杀基因治疗策略的探讨。此外，靶向治疗与免疫治疗的新策略也为抗癌治疗开辟了新途径。通过这些文献资料的分类整理与分析，本文旨在为未来原发性肝癌治疗方法和药物研发提供更广泛的视野和可能的指导方向。
With the deepening of medical research, significant progress has been made in treatment strategies and drug development for primary liver cancer, with a special emphasis on hepatocellular carcinoma (HCC). This literature review summarizes the latest research findings in disease mechanisms, epidemiology, treatment methods, and drug development related to primary liver cancer. Focusing on disease mechanisms and biomarkers, studies investigate the correlation between IVIM-DWI parameters with VEGF and MMPs expression, and the role of antisense non-coding RNA at the INK4 locus, providing a basis for identifying new treatment targets. Epidemiological and clinical feature analysis reveals variations in HCC incidence across different populations and age groups, offering data support for disease prevention and early intervention. In terms of treatment, the efficacy of traditional transarterial chemoembolization (TACE) and its combination with other therapies are evaluated, alongside explorations in targeted suicide gene therapy strategies. Moreover, new approaches in targeted and immunotherapy strategies open up novel pathways for anti-cancer treatments. Through organized categorization and analysis of these scholarly articles, this review aims to broaden the perspective and provide possible guidance for future treatment methods and drug developments for primary liver cancer.